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Background: Evidence-based guidelines recommend aspirin (ASA) for the prevention of cardiovascular (CVD) events in individuals with a prior 
event (secondary prevention) or diabetics > 40 years. Prior studies suggest the use of ASA may not be optimal in at-risk populations. We evaluated 
the self-reported use of ASA in > 350,000 individuals across the U.S.
Methods: Data from 127 healthcare centers across the U.S. that used a commercial, web-based CVD risk assessment tool (HeartAware™) were 
analyzed. Participants who volunteered for the survey responded to questions about their CVD risk factors, the presence or absence of coronary, 
cerebral, peripheral arterial disease, diabetes, and medication use including daily ASA. Individuals who, based on guidelines should be taking ASA 
(diabetics > 40 years or a history of angina, stroke, myocardial infarction, or any coronary revascularization) were included in the analysis. Univariate 
and multivariate logistic regression analyses for odds ratios (OR) were performed to find factors significantly associated with ASA intake.
Results: Among 350,716 respondents, 68% were female. Of 33,259 individuals who should be taking ASA based on guideline recommendations, 
only 54% ( 95% confidence interval (CI) 53.5-54.5%) reported the use of ASA. Multivariate regression analysis found that male gender (OR=1.7;CI 
1.6 -1.8) imparted a higher chance of taking ASA while African-Americans (OR=0.6; 95% CI 0.6-0.8) had a lesser chance of taking ASA. Other factors 
that contributed significantly to aspirin adherence were age > 65 years and a reported relationship with a healthcare provider. All p values were 
<0.0001. We expect that any bias introduced by self-reporting would likely favor the use of ASA so the actual rate of ASA use may be even lower.
Conclusions: These data from one of the largest cross-sectional cohorts ever studied show that 46% of patients who should be taking ASA for 
prevention either are not following or are not receiving this guideline recommendation. This identifies a simple and inexpensive opportunity to 
improve CVD outcomes especially in at-risk populations including women and African Americans.
